Abstract
In order to verify if quantitative assessment of the WT1 transcript amount by the real time quantitative PCR (RQ-PCR) can be used as a marker for minimal residual disease detection, the WT1 transcript amount was determined in BM and PB samples of patients with myeloid and lymphoid acute leukemia, in normal controls, in regenerating bone marrow samples and in purified CD34-positive cells from normal subjects. In 10 patients bearing a fusion gene transcript suitable for minimal residual disease quantitative assessment, we performed a simultaneous analysis of the WT1 and of the fusion-gene transcript at sequential time intervals during follow-up. Sequential WT1 analysis was also performed in five AML patients lacking additional molecular markers. The data obtained show that normal and regenerating BM samples and purified CD34-positive cells consistently express minimal amounts of WT1 transcript and that this is extremely low and frequently undetectable in normal PB. By contrast, high levels of WT1 expression are present in the BM and PB samples of all acute leukemia (AL) cases at diagnosis. The WT1 levels during follow-up were found to follow the pattern of the other molecular markers (fusion gene transcripts) used for MRD monitoring and increased WT1expression in the BM and/or PB during follow-up of AL patients was always found to be predictive of an impending hematological relapse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 28: 1731–1738
Cave H, van der Werfften Bosch J, Suciu S, Guidal C, Waterkeeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group N Engl J Med 1998 27: 591–598
Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG . Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood 1999 94: 12–22
Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MG, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F . Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. GIMEMA-AIEOP Multicenter ‘AIDA’ Trial Blood 1998 92: 784–789
Call KM, Glaser T, Ito CY, Bukler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH . Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus Cell 1990 60: 509–520
Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Flecher J, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, Harber DA . The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma Nat Genet 1993 4: 415–420
Baird PN, Simmons PJ . Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis Exp Hematol 1997 25: 312–320
Miwa H, Beran M, Saunders GF . Expression of the Wilms tumor gene (WT1) in human leukemias Leukemia 1992 6: 405–409
Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I . Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells Leukemia 1993 7: 970–977
Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Tishimoto T, Sugiyama H . Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia Blood 1997 89: 1405–1412
Inoue K, Sugiyama H, Ogawa H, Nakagava M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo Y, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T . WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia Blood 1994 84: 3071–3079
Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW . The detection of WT-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation Bone Marrow Transplant 2000 25: 91–96
Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K, Sillaber C, Laczika K, Mitterbauer M, Zochbauer S, Mannhalter C, Haas OA, Lechner K, Jager U, Gaiger A . Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia Leukemia 1997 11: 639–643
Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, Tisljiar K, Priglinger S, Laczika K, Mitterbauer M, Novak M, Mitterbauer G, Mannhalter C, Haas OA, Lechner K, Jager U . Detection of WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia Leukemia 1998 12: 1886–1894
Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P, Schmidt A . Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias Br J Haematol 2001 114: 313–318
Sakatani T, Shimazaki C, Hirai H, Okano A, Hatsuse M, Okamoto A, Takahashi R, Ashihara E, Inaba T, Yokota H, Nakahara K, Hirai H, Nakagawa M . Early relapse after high-dose chemotherapy rescued by tumor-free autologous peripheral blood stem cells in acute lymphoblastic leukemia: importance of monitoring for WT1 mRNA quantitatively Leuk Lymphoma 2001 42: 225–229
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Perreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A . Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia 1999 13: 1901–1928
Miltenyi S, Muller W, Weichel W, Radbruch A . High gradient magnetic cell separation with MACS Cytometry 1990 11: 231–238
Gabert J, Beillard E, Bi W, Pallisgaard N, Gottardi E, Cazzaniga G, Barbany G, Cavè H, Cayuela JM, Grimwade D, Aerts JLE, van der Velden VHJ, Pane F, Saglio G, van Dongen JJM . European SANCO concerted action. European standardization and quality control program of Real Time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukemia patients Blood 2000 96: 1343 (Abstr.)
Gabert J, Beillard E, van der Velden VHJ, Bi W, Pallisgaard N, De Micheli D, Cazzaniga G, Barbany G, Cayuela JM, Pane F, Cavè H, Grimwade D, Aerts JLE, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJM . Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for minimal residual disease detection in leukemia – A Europe Against Cancer Program (In preparation)
Pallisgaard N, Hokland P, Bi W, Dee R, Van Der Schoot E, Delabesse E, Macintyre E, van der Velden VHJ, van Dongen JJM, Gottardi E, Saglio G, Watzinger F, Lion T, Beillard E, Gabert J . Control genes for Real-Time Quantitative RT-PCR in leukemia. A report from SANCO Concerted Action within the Europe Against Cancer Program (In preparation)
Spinsanti P, de Grazia U, Faggioni A, Frati L, Calogero A, Ragona G . Wilms’ tumor gene expression by normal and malignant human B lymphocytes Leuk Lymphoma 2000 38: 611–619
Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H . Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels Blood 1996 88: 2267–2278
Acknowledgements
This work has been supported by grants from CNR (Progetto Finalizzato Biotecnologie), MURST-COFIN 2000, AIL (Associazione Italiana contro le Leucemie- Gimema-AML Project), AIRC (Associazione Italiana per la Ricerca sul Cancro) and Associazione Italiana Amici di Josè Carreras.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cilloni, D., Gottardi, E., De Micheli, D. et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 2115–2121 (2002). https://doi.org/10.1038/sj.leu.2402675
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402675
Keywords
This article is cited by
-
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy
International Journal of Clinical Oncology (2024)
-
High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk
Clinical and Experimental Medicine (2023)
-
Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia
Clinical and Translational Oncology (2023)
-
Wilms tumor 1 gene expression in acute myeloid leukemia: prognostic significance and usefulness in minimal residual disease monitoring—a case–control study
Egyptian Journal of Medical Human Genetics (2022)
-
Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen
Nature Biomedical Engineering (2020)